Journal
MACROMOLECULAR BIOSCIENCE
Volume 19, Issue 4, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/mabi.201800362
Keywords
biomaterials; drug delivery; polymer-lipid nanoparticles; vaccine delivery
Funding
- NIH [HD075703, AI112002]
- National Science Foundation Graduate Research Fellowship Program [DGE-1256082]
- Achievement Rewards for College Scientists (ARCS) Foundation Scholar Award
Ask authors/readers for more resources
Significant efforts have been invested in finding a delivery system that can encapsulate and deliver therapeutics. Core-shell polymer-lipid hybrid nanoparticles have been studied as a promising platform because of their mechanical stability, narrow size distribution, biocompatibility, and ability to co-deliver diverse drugs. Here, novel core-shell nanoparticles based on a poly(lactic-co-glycolic acid) (PLGA) core and multilamellar lipid shell are designed, where the lipid bilayers are crosslinked between the two adjacent bilayers (PLGA-ICMVs). The cross-platform performance of the nanoparticles to other polymer-lipid hybrid platforms is examined, including physicochemical characteristics, ability to encapsulate a variety of therapeutics, biocompatibility, and functionality as a vaccine delivery platform. Differential abilities of nanoparticle systems to encapsulate distinct pharmaceutics are observed, which suggest careful consideration of the platform chosen depending on the therapeutic agent and desired function. The novel PLGA-ICMV platform herein demonstrates great potential in stably encapsulating water-soluble agents and therefore is an attractive platform for therapeutic delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available